Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
Abatacept achieved an ORR of 49% and sustained reduction in prednisone dosing over time in patients with steroid-refractory chronic GVHD.
Format: Microsoft PowerPoint (.ppt)
File Size: 157 KB
Released: December 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings